304 related articles for article (PubMed ID: 17391740)
1. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients.
Pawlak K; Naumnik B; Brzósko S; Pawlak D; Myśliwiec M
Am J Nephrol; 2004; 24(1):154-61. PubMed ID: 14726627
[TBL] [Abstract][Full Text] [Related]
4. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.
Pawlak K; Domaniewski T; Mysliwiec M; Pawlak D
Thromb Res; 2009 Sep; 124(4):452-7. PubMed ID: 19477487
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes.
Pawlak K; Pawlak D; Mysliwiec M
Nephron Clin Pract; 2007; 107(1):c20-5. PubMed ID: 17671395
[TBL] [Abstract][Full Text] [Related]
6. Long-term erythropoietin therapy does not affect metalloproteinases and their inhibitor levels, oxidative stress and inflammation in hemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Am J Nephrol; 2007; 27(3):221-5. PubMed ID: 17384500
[TBL] [Abstract][Full Text] [Related]
7. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
8. Does treatment of renal anemia with recombinant erythropoietin influence oxidative stress in hemodialysis patients?
Sommerburg O; Grune T; Hampl H; Riedel E; Ehrich JH; Siems WG
Clin Nephrol; 2000 Feb; 53(1 Suppl):S23-9. PubMed ID: 10746802
[TBL] [Abstract][Full Text] [Related]
9. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
10. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients.
Pawlak K; Zolbach K; Borawski J; Mysliwiec M; Kovalchuk O; Chyczewski L; Pawlak D
Thromb Res; 2008; 123(1):166-70. PubMed ID: 18452978
[TBL] [Abstract][Full Text] [Related]
11. Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients.
Kahraman S; Yilmaz R; Kirkpantur A; Genctoy G; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Nephrology (Carlton); 2005 Jun; 10(3):264-9. PubMed ID: 15958039
[TBL] [Abstract][Full Text] [Related]
12. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
15. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
16. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
17. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
18. [Method of dialysis therapy and selected markers of oxidative stress and endothelial injury in patients with chronic renal failure].
Pawlak K; Pawlak D; Myśliwiec M
Pol Arch Med Wewn; 2005 Jan; 113(1):21-6. PubMed ID: 16130597
[TBL] [Abstract][Full Text] [Related]
19. Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients.
Reuter SE; Faull RJ; Ranieri E; Evans AM
Nephrol Dial Transplant; 2009 Mar; 24(3):990-6. PubMed ID: 18987259
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
